Labcorp Holdings Inc. (NYSE:LH - Get Free Report) EVP Amy Summy sold 365 shares of the company's stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $372.58, for a total value of $135,991.70. Following the completion of the sale, the executive vice president owned 6,590 shares in the company, valued at $2,455,302.20. This represents a 5.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Labcorp Stock Performance
NYSE LH opened at $368.93 on Wednesday. The stock has a market cap of $29.96 billion, a PE ratio of 30.26, a P/E/G ratio of 2.10 and a beta of 0.86. The firm has a 50-day moving average of $331.39 and a 200-day moving average of $293.59. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.22 and a current ratio of 1.41. Labcorp Holdings Inc. has a 52-week low of $245.00 and a 52-week high of $375.10.
Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.64 by $0.14. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.76 billion. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The firm's quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the company posted $4.18 EPS. On average, sell-side analysts anticipate that Labcorp Holdings Inc. will post 18.51 EPS for the current year.
Labcorp Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp's dividend payout ratio (DPR) is 23.63%.
Analysts Set New Price Targets
Several research analysts have recently issued reports on LH shares. Truist Financial upped their price target on shares of Labcorp from $365.00 to $395.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. Leerink Partners set a $410.00 target price on Labcorp in a report on Wednesday, October 28th. UBS Group upped their target price on shares of Labcorp from $380.00 to $420.00 and gave the stock a "buy" rating in a research note on Thursday, October 29th. Robert W. Baird raised their price objective on shares of Labcorp from $361.00 to $396.00 and gave the stock an "outperform" rating in a report on Thursday, October 29th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Labcorp from $330.00 to $360.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Labcorp has a consensus rating of "Moderate Buy" and an average target price of $369.08.
View Our Latest Stock Report on LH
Hedge Funds Weigh In On Labcorp
Several institutional investors and hedge funds have recently bought and sold shares of LH. Zacks Investment Management grew its stake in shares of Labcorp by 4.2% in the third quarter. Zacks Investment Management now owns 89,168 shares of the medical research company's stock worth $27,474,000 after acquiring an additional 3,600 shares during the last quarter. Integrated Wealth Concepts LLC raised its holdings in shares of Labcorp by 45.4% during the third quarter. Integrated Wealth Concepts LLC now owns 2,261 shares of the medical research company's stock valued at $697,000 after purchasing an additional 706 shares during the last quarter. CapitalatWork S.A. purchased a new stake in Labcorp during the 3rd quarter valued at $64,306,000. Virtu Financial LLC bought a new position in Labcorp in the third quarter valued at about $3,046,000. Finally, Allworth Financial LP lifted its stake in shares of Labcorp by 15.2% in the 3rd quarter. Allworth Financial LP now owns 6,868 shares of the medical research company's stock worth $2,116,000 after purchasing an additional 905 shares during the period. 95.94% of the stock is currently owned by institutional investors.
Labcorp Company Profile
(
Get Free Report)
Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Labcorp, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Labcorp wasn't on the list.
While Labcorp currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.